BACKGROUND: Previous studies identified B cell gene signatures and predominance of specific B cell subsets as a marker of operational tolerance after kidney transplantation. These findings suggested a role for B cells in the establishment or maintenance of tolerance. Here we analyzed B cell recovery in 4 subjects, 3 of whom achieved tolerance after combined kidney/bone marrow transplantation. METHODS: Peripheral B cell subsets were examined longitudinally by flow cytometry. Immunoglobulin heavy chain repertoire analysis was performed using next-generation sequencing. Lastly, the patients' serum reactivity to HLA was assessed by Luminex. RESULTS: B cell counts recovered approximately 1 year posttransplant except for 1 subject who experienced delayed reconstitution. This subject resumed immunosuppression for acute rejection at 10 months posttransplant and underwent preemptive retransplantation at 3 years for chronic rejection. B cell recovery was accompanied by a high frequency of CD20 + CD24CD38 transitional B cells and a diversified clonal repertoire. However, all 4 subjects showed prevalence of CD20 + CD27+ memory B cells around 6 months posttransplant when B cell counts were still low and the clonal B cell repertoire very limited. The predominance of memory B cells was also associated with high levels of somatically mutated immunoglobulin heavy chain variable sequences and transient serum reactivity to HLA. CONCLUSIONS: Our observations reveal the presence of memory B cells early posttransplant that likely escaped the preparative regimen at a time consistent with the establishment of tolerance. Further studies are warranted to characterize the functional properties of these persisting memory cells and evaluate their potential contribution to tolerance induction.
BACKGROUND: Previous studies identified B cell gene signatures and predominance of specific B cell subsets as a marker of operational tolerance after kidney transplantation. These findings suggested a role for B cells in the establishment or maintenance of tolerance. Here we analyzed B cell recovery in 4 subjects, 3 of whom achieved tolerance after combined kidney/bone marrow transplantation. METHODS: Peripheral B cell subsets were examined longitudinally by flow cytometry. Immunoglobulin heavy chain repertoire analysis was performed using next-generation sequencing. Lastly, the patients' serum reactivity to HLA was assessed by Luminex. RESULTS: B cell counts recovered approximately 1 year posttransplant except for 1 subject who experienced delayed reconstitution. This subject resumed immunosuppression for acute rejection at 10 months posttransplant and underwent preemptive retransplantation at 3 years for chronic rejection. B cell recovery was accompanied by a high frequency of CD20 + CD24CD38 transitional B cells and a diversified clonal repertoire. However, all 4 subjects showed prevalence of CD20 + CD27+ memory B cells around 6 months posttransplant when B cell counts were still low and the clonal B cell repertoire very limited. The predominance of memory B cells was also associated with high levels of somatically mutated immunoglobulin heavy chain variable sequences and transient serum reactivity to HLA. CONCLUSIONS: Our observations reveal the presence of memory B cells early posttransplant that likely escaped the preparative regimen at a time consistent with the establishment of tolerance. Further studies are warranted to characterize the functional properties of these persisting memory cells and evaluate their potential contribution to tolerance induction.
Authors: Kenneth A Newell; Adam Asare; Allan D Kirk; Trang D Gisler; Kasia Bourcier; Manikkam Suthanthiran; William J Burlingham; William H Marks; Ignacio Sanz; Robert I Lechler; Maria P Hernandez-Fuentes; Laurence A Turka; Vicki L Seyfert-Margolis Journal: J Clin Invest Date: 2010-05-24 Impact factor: 14.808
Authors: Gary P Sims; Rachel Ettinger; Yuko Shirota; Cheryl H Yarboro; Gabor G Illei; Peter E Lipsky Journal: Blood Date: 2005-02-08 Impact factor: 22.113
Authors: F Porcheray; W Wong; S L Saidman; J De Vito; T C Girouard; M Chittenden; J Shaffer; N Tolkoff-Rubin; B R Dey; T R Spitzer; R B Colvin; A B Cosimi; T Kawai; D H Sachs; M Sykes; E Zorn Journal: Am J Transplant Date: 2009-07-16 Impact factor: 8.086
Authors: Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri Journal: Immunity Date: 2010-01-14 Impact factor: 31.745
Authors: S Shabir; J Girdlestone; D Briggs; B Kaul; H Smith; S Daga; S Chand; S Jham; C Navarrete; L Harper; S Ball; R Borrows Journal: Am J Transplant Date: 2015-03-23 Impact factor: 8.086
Authors: Chun-Shu Wong; Clarisa M Buckner; Silvia Lucena Lage; Luxin Pei; Felipe L Assis; Eric W Dahlstrom; Sarah L Anzick; Kimmo Virtaneva; Adam Rupert; Jeremy L Davis; Ting Zhou; Elizabeth Laidlaw; Maura Manion; Frances Galindo; Megan Anderson; Catherine A Seamon; Michael C Sneller; Andrea Lisco; Claire Deleage; Stefania Pittaluga; Susan Moir; Irini Sereti Journal: Front Immunol Date: 2021-12-01 Impact factor: 7.561
Authors: Frances T Lee; Anil Dangi; Sahil Shah; Melanie Burnette; Yong-Guang Yang; Allan D Kirk; Bernhard J Hering; Stephen D Miller; Xunrong Luo Journal: Am J Transplant Date: 2020-01-21 Impact factor: 8.086